Trusted Outcomes
Delivering real-world evidence
Outcomes you can trust
The Global Registry for Endovascular Aortic Treatment (GREAT) is the largest real-world aortic registry, encompassing 28 aortic pathologies. With a 10-year patient follow-up, it provides trustworthy long-term results and real-world data.1,2
5,000+
patients worldwidea
10-year
ongoing follow-up
~40
peer-reviewed publications
Real-world
durability and performance of the GORE® EXCLUDER® AAA Endoprosthesis
The ability to track such a large number of patients over an extended period of time is something that clearly sets GREAT apart from other registries. This sample will provide us with an opportunity to measure patient successes and outcomes that help us make continued improvements in aortic endovascular repair.
This data includes procedural and clinical outcomes, covering 28 different pathologies along the aorta, as well as information on the devices used, patient medical history, demographics and disease state.
Device construction, materials and stent design all have significant impact on the overall outcome of aortic procedures. The GORE® EXCLUDER® AAA Endoprosthesis demonstrates this importance with its proven track record of 0.1% migration and fracture rates along with very low type I, III and IV endoleak rates.2
Explore the data from the largest real-world aortic registry
Long-term durability for TEVAR and EVAR through 5-years
TEVAR 85.5%
Freedom from device-related reinterventions with the Conformable GORE® TAG® Thoracic Endoprosthesisb through 5-year follow-up
EVAR 94.7%
Freedom from device-related reinterventions with GORE® EXCLUDER® AAA Endoprosthesisc through 5-year follow-up
| TEVAR | |
|---|---|
| Procedural | |
| Patients (n) | 778 |
| Procedural survival | 99.7% |
| Access complication | 2.8% |
| Through 5-years | |
| Migration | 0.3% |
| Fracture | 0% |
| Compression | 0% |
| Conversion to open repair | 1.8% |
| Aortic-related mortality | 3% |
| EVAR | |
|---|---|
| Through 5-years | |
| Patients (n) | 3,216 |
| Migration | 0.1% |
| Type 1 A endoleak | 1.1% |
| Type III endoleak | 0.2% |
| Conversion to open repair | 0.9% |
| Aortic-related mortality | 1.2% |
| Limb occlusion | 0.7% |
10-year data now published, reinforcing long-term efficacy and safety outcomes1,2
The European C3 module of GREAT aims to assess the performance of the GORE® EXCLUDER® AAA Endoprosthesis featuring C3® Delivery system in AAA treatment.2
The analysis provides real-world evidence on long-term device durability, aneurysm sac behaviour, reintervention rates and overall clinical outcomes in patients treated for abdominal aortic aneurysms.1,2
Study design
10-year sac dynamics
Of the 160 patients available for analysis, the imaging in years 7–10 demonstrated stable or decreased aneurysmal sac size in > 80%.1
The GORE® EXCLUDER® AAA Endoprosthesis has proven long‑term aneurysm sac regression1
EVAR durability, proven over a decade1,2
99.5%
Freedom from
stent graft migrationd
97.2%
Freedom from
type Ia endoleak
99.0%
Freedom from
type Ib endoleak
The GORE® EXCLUDER® AAA Endoprosthesis has proven long-term durability, secure placement and effective sealing through 10-years1,2
Low rates of aortic-related mortality and major complicationse,1,2
| European GREAT 10-12 cohort through 10-years (n = 396) | |
|---|---|
| Freedom from aneurysm-related mortality | 98.6% |
| Freedom from aortic rupture | 99.1% |
| Freedom from conversion to open/explant | 97.7% |
| Freedom from limb occlusion | 99.0% |
| Freedom from device-related reintervention | 80.6% |
OUTCOMES MATTER
With long-term performance and safety data, you can focus your efforts directly on your patients’ priorities
The 10-year results from the European C3 module of the GREAT registry demonstrate that the GORE® EXCLUDER® AAA Endoprosthesis represents:
- A safe and durable EVAR device for the treatment of infrarenal aortic aneurysms1,2
- Low rates of aortic-related mortality and major complicationse,1,2
Discover more insights from the GREAT Registry
Dennis R. Gable, M.D.
Ross Milner, M.D.
a Of the 5,059 patients enrolled, 4,996 were included in the overall registry follow-up. The European GREAT 10–12 arm specifically included 396 patients.
b W. L. Gore & Associates. 'GREAT' Global Registry for Endovascular Aortic Treatment - Outcomes Evaluation. Bethesda, MD: National Library of Medicine; 2012. Available from: NLM Identifier: NCT01658787. Published August 7, 2012. Updated: October 10, 2024. Accessed December 2025. https://clinicaltrials.gov/ct2/show/NCT01658787
c GREAT. n = 4,996. To calculate the overall event rates from procedure through end of study period, all subjects who could have had events, regardless of length of follow-up, were included. For outcome data, GREAT only collects site reported serious adverse events.
d Does not include ‘device placement at incorrect location’ or similar coded MedDRA term.
e Major complications included secondary ruptures and conversions to open repair.
- Bischoff M, Verhoeven E, Katsargyris A, Bockler D. Long term real world performance of the Gore Excluder AAA Endoprosthesis featuring the C3 delivery system: 10 year results from the European C3 module of the GREAT Registry. European Journal of Vascular & Endovascular Surgery 2025;S1078-5884(25)01187–6.
- 10-year EVAR results from a post market registry – Presented on Thursday, 24th April 2025, Charing Cross Symposium, by Moritz Bischoff.
- Long C, Katsargyris A, Milner R, Verhoeven E. Five-year results for abdominal aortic aneurysm repair with the GORE® EXCLUDER® device: Insights from the Gore Global Registry for Endovascular Aortic Treatment (GREAT). Annals of Vascular Surgery 2024;106:247–254.
Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly
GORE® EXCLUDER® AAA Endoprosthesis
INDICATIONS FOR USE IN EUROPE:
Trunk-Ipsilateral Leg Endoprosthesis and Contralateral Leg Endoprosthesis Components
The GORE® EXCLUDER® AAA Endoprosthesis is intended to exclude the aneurysm from the blood circulation in patients diagnosed with infrarenal abdominal aortic aneurysm (AAA) disease and who have appropriate anatomy as described below:
- Adequate iliac / femoral access
- Infrarenal aortic neck treatment diameter range of 19–32 mm and a minimum aortic neck length of 15 mm
- Proximal aortic neck angulation ≤ 60°
- Iliac artery treatment diameter range of 8–25 mm and iliac distal vessel seal zone length of at least 10 mm
Aortic Extender Endoprosthesis and Iliac Extender Endoprosthesis Components
The Aortic and Iliac Extender Endoprostheses are intended to be used after deployment of the GORE® EXCLUDER® AAA Endoprosthesis. These extensions are intended to be used when additional length and / or sealing for aneurysmal exclusion is desired.
CONTRAINDICATIONS: The GORE® EXCLUDER® AAA Endoprosthesis is contraindicated in:
- Patients with known sensitivities or allergies to the device materials
- Patients with a systemic infection who may be at increased risk of endovascular graft infection
GORE® TAG® Conformable Thoracic Stent Graft
INDICATIONS FOR USE IN EUROPE: The GORE® TAG® Conformable Thoracic Stent Graft is indicated for endovascular repair of all lesions of the descending thoracic aorta, including isolated lesions, such as aneurysm and traumatic transection, and Type B dissections.
CONTRAINDICATIONS: The GORE® TAG® Conformable Thoracic Stent Graft is contraindicated in:
- Patients with known sensitivities or allergies to the device materials
- Patients with a systemic infection who may be at increased risk of endovascular graft infection